Use of akkermansia for treating metabolic disorders

a technology of akkermansia and metabolic disorders, which is applied in the field of treatment of metabolic disorders, can solve the problems that the beneficial effect of direct administration of akkermansia muciniphila has never been described, nor suggested, and achieves the effects of increasing energy expenditure, increasing energy expenditure of said subjects, and increasing energy expenditur

Pending Publication Date: 2015-10-29
UNIVERSITE CATHOLIQUE DE LOUVAIN +1
View PDF4 Cites 37 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0117]In one embodiment of the invention, the administration of Akkermansia muciniphila or a fragment thereof to a subject increases energy expenditure of said subject, preferably without impacting the food intake of said subject.
[0118]The present invention thus also relates to a method of increasing energy expenditure of a subject, comprising administering Akkermansia muciniphila or a fragment thereof, or a composition, pharmaceutical composition, cosmetic composition or medicament of the invention to the subject, preferably in a therapeutically or cosmetically effective amount. Preferably, the method of the invention does not comprise or further comprise modulating the food intake of said subject. In one embodiment of the invention, the method of the invention increases energy expenditure, thereby inducing durable weight loss in the subject, and thereby treating metabolic disorders in said subject, such as, for example, obesity related metabolic disorders.
[0119]In one embodiment, the administration of Akkermansia muciniphila or a fragment thereof to a subject increases satiety in said subject. Consequently, according to this embodiment, the method of the invention increases satiety in a subject, thereby inducing durable weight loss in the subject, and thereby treating metabolic disorders in said subject, such as, for example, obesity related metabolic disorders.

Problems solved by technology

However, this may be an indirect effect due to the insensitivity of intestinal Akkermansia spp. to the used antibiotic.
Moreover, to the Applicant knowledge, no beneficial effect of the direct administration of Akkermansia muciniphila has never been described, nor suggested.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of akkermansia for treating metabolic disorders
  • Use of akkermansia for treating metabolic disorders
  • Use of akkermansia for treating metabolic disorders

Examples

Experimental program
Comparison scheme
Effect test

examples

[0132]The present invention is further illustrated by the following examples.

Materials and Methods

Mice

[0133]Ob / Ob Experiment:

[0134]ob / ob versus lean study: Six-week-old ob / ob (n=5 / group) mice (C57BL / 6 background, Jackson-Laboratory, Bar Harbor, Me., USA) were housed in a controlled environment (12-h daylight cycle, lights-off at 6-pm) in groups of two or three mice / cage, with free access to food and water. The mice were fed a control diet (A04, Villemoisson-sur-Orge, France) for 16 weeks. Cecal content was harvested immersed in liquid nitrogen, and stored at −80° C., for further Akkermansia muciniphila analysis.

[0135]Ob / Ob Prebiotic Study:

[0136]Six-week-old ob / ob (n=10 / group) mice (C57BL / 6 background, Jackson-Laboratory, Bar Harbor, Me., USA) were housed in a controlled environment (12-h daylight cycle, lights-off at 6-pm) in groups of two mice / cage, with free access to food and water. The mice were fed a control diet (Ob-CT) (A04, Villemoisson-sur-Orge, France) or a control diet su...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

Description

FIELD OF INVENTION[0001]The present invention relates to the treatment of metabolic disorders, such as, for example, metabolic disorders related to overweight and obesity, such as, for example, Diabetes Mellitus or high cholesterol. The present invention more specifically relates to a composition comprising Akkermansia spp or fragments thereof for treating a metabolic disorder.BACKGROUND OF INVENTION[0002]Obesity is a worldwide problem, with an estimated number of obese adults of about 250 million. This epidemic of obesity is correlated with a great increase in the prevalence of obesity-related disorders, such as, for example, Diabetes, hypertension, cardiac pathologies and liver diseases. Due to these highly disabling pathologies, obesity is currently considered in western countries as one of the most important public health problem. There is thus a real need of compositions and methods for treating or preventing obesity and / or obesity-related disorders.[0003]Obesity and obesity-re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/74A61K9/00A61K35/741A23L2/38
CPCA61K35/74A61K9/0053A61K35/741A61P3/00A61P1/16A61P11/00A61P11/06A61P19/02A61P25/00A61P25/28A61P3/04A61P35/00A61P3/06A61P37/02A61P37/04A61P43/00A61P9/00A61P9/10A61P9/12A61P3/10Y02A50/30A23L33/135A61P1/00A23V2002/00A23V2200/32
Inventor CANI, PATRICEEVERARD, AMANDINEBELZER, CLARADE VOS, WILLEM
Owner UNIVERSITE CATHOLIQUE DE LOUVAIN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products